Akademik Veri Yönetim Sistemi
Archiv der Pharmazie, cilt.359, sa.5, 2026 (SCI-Expanded, Scopus)
Tamoxifen (TMX) resistance presents a significant challenge in the treatment of ER+ breast cancer. In this study, four novel tamoxifen-based dimers were synthesized and evaluated for their antitumor activities. Among these, (Z,Z)-1 exhibited potent antiproliferative effects in ER+ cells, demonstrating selective toxicity toward cancer cells over normal cells. (Z,Z)-1 significantly outperformed tamoxifen with IC50 values of 9.18 μM (24 h) and 6.86 μM (48 h) against MCF-7 cells. Additionally, it showed greater selectivity toward ER+ breast cancer cells compared with both triple-negative cancer cells and non-cancerous cells. Mechanistic studies indicated that (Z,Z)-1 induces apoptosis in MCF-7 cells through a cell-cycle-independent mechanism, unlike TMX, which arrests cells at the G0/G1 phase. These findings suggest that (Z,Z)-1 may be a promising candidate for further development as an alternative to tamoxifen therapy in ER+ breast cancer treatment. The docking studies revealed that (Z,Z)-1 exhibits the strong binding affinity to ERα, highlighting its potential as a promising therapeutic candidate for ER+ breast cancer treatment.